NXTC

NextCure, Inc.

Nasdaq · Pharmaceutical Preparations · Inc. DE · CIK 0001661059

$10.11 +4.82% $34.8M

Vol

Market Cap$34.8M

Cap SizeNano Cap

Analyst ConsensusStrong Buy (89%)

Inst. Holders4 funds

Inst. Value$1.8M

Inst. Activity2 buys / 0 sells

SEC Reports3

Press Releases3

Exchange Nasdaq·Sector Pharmaceutical Preparations·Inc. DE·CIK 0001661059·Prev Close $9.65

Recent Activity

May 7, 2026 SEC

NextCure reported Q1 2026 net loss of $9.8M ($1.87 per share), in line with consensus of $1.85. Cash burn continues with

8-K — Impact 3/10

May 7, 2026 earnings

NextCure Provides Business Update and Reports First Quarter 2026 Financial Results

BELTSVILLE, Md., May 07, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Track

Apr 24, 2026 SEC

NextCure, Inc. filed a definitive proxy statement for its 2026 Annual Meeting, where shareholders will vote on the elect

DEFA14A — Impact 3/10

Mar 5, 2026 SEC

NextCure reported its full year 2025 financial results, showing a net loss of $55.8 million, a slight increase from $55.

8-K — Impact 5/10

Jan 30, 2026 Insider

Cobourn Steven P. sold 14,670 shares

Chief Financial Officer @ $0.00 ($0.00)

Jan 30, 2026 Insider

Richman Michael sold 38,190 shares

President & CEO @ $0.00 ($0.00)

Jan 30, 2026 Insider

Mayer Timothy sold 14,670 shares

Chief Operating Officer @ $0.00 ($0.00)

Inst.

VANGUARD GROUP INC — ADD

91,910 shares ($1.3M)

Price Targets

$19.33 +91.2% upside Strong Buy

Current $10.11 Low $15.00 Median $18.00 High $25.00 3 analysts

$15.00 $25.00

Analyst Ratings

Strong Buy89% buy · 9 analysts

3Strong Buy

5Buy

1Hold

0Sell

0Strong Sell

Recent Analyst Actions

Date	Firm	Action	Rating
May 11, 2026	LUCID CAPITAL MARKETS	INITIATE	Buy

Earnings Estimates

Period	EPS Est.	Range	Growth	#
Current Q	$-1.86 ▲ +6.8%	$-1.89 — $-1.84	83% YoY	2
Next Q	$-1.63 ▲ +21.3%	$-1.96 — $-1.30	49% YoY	2
Current FY	$-6.93 ▲ +15.6%	$-7.69 — $-6.17	65% YoY	2
Next FY	$-8.35 ▼ -32.3%	$-10.41 — $-5.49	-20% YoY	3

Latest Reports

NEUTRAL 8-K 3/10

NextCure reported Q1 2026 net loss of $9.8M ($1.87 per share), in line with consensus of $1.85. Cash burn continues with

May 7, 2026

NEUTRAL Press 4/10

NextCure announced initiation of dose optimization for its CDH6-directed ADC SIM0505 in platinum-resistant ovarian cance

May 4, 2026

NEUTRAL DEFA14A 3/10

NextCure, Inc. filed a definitive proxy statement for its 2026 Annual Meeting, where shareholders will vote on the elect

Apr 24, 2026

Top Institutional Holders

Fund	Value	Move
VANGUARD GROUP INC	$1.3M	ADD
RENAISSANCE TECHNOLOGIES LLC	$477.3K	NEW
BANK OF AMERICA CORP	$2.5K	DOUBLED
MORGAN STANLEY	$937.00	—

Recent Insider Trades

Date	Insider	Type	Value
Jan 30, 2026	Cobourn Steven	A	$0.00
Jan 30, 2026	Richman Michael	A	$0.00
Jan 30, 2026	Mayer Timothy	A	$0.00
Jan 30, 2026	Guha Udayan	A	$0.00
Jan 30, 2026	Kundu Sourav	A	$0.00

4 institutional holders with $1.8M total value (125,783 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, BANK. Net buying activity: 2 institutions added/increased vs 0 reduced.

Top Institutional Holders — 2025-Q4

#	Fund	Shares	Value	% of Tracked	Last Move
1	VANGUARD GROUP INC	91,910	$1.3M	73.1%	ADD +35.2%
2	RENAISSANCE TECHNOLOGIES LLC	33,634	$477.3K	26.7%	NEW
3	BANK OF AMERICA CORP /DE/	173	$2.5K	0.1%	DOUBLED +652.2%
4	MORGAN STANLEY	66	$937.00	0.1%	—

Recent Position Changes

Fund	Action	Prev Shares	Curr Shares	Change %	Value	Quarter
VANGUARD GROUP INC	ADD	67,983	91,910	+35.2%	$1.3M	2025-Q4
BANK OF AMERICA CORP /DE/	DOUBLED	23	173	+652.2%	$2.5K	2025-Q4
VANGUARD GROUP INC	NEW	—	67,983	—	$398.4K	2025-Q3
RENAISSANCE TECHNOLOGIES LLC	NEW	—	28,334	—	$166.0K	2025-Q3
VANGUARD GROUP INC	EXIT	872,020	0	-100.0%	$0.00	2025-Q3
RENAISSANCE TECHNOLOGIES LLC	EXIT	500,935	0	-100.0%	$0.00	2025-Q3
UBS Group AG	ADD	8,537	12,299	+44.1%	$5.7K	2025-Q2
UBS Group AG	DOUBLED	4,202	8,537	+103.2%	$4.1K	2025-Q1
RENAISSANCE TECHNOLOGIES LLC	ADD	406,000	519,300	+27.9%	$400.4K	2024-Q4
CITADEL ADVISORS LLC	ADD	55,954	78,678	+40.6%	$60.7K	2024-Q4
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	EXIT	10,000	0	-100.0%	$0.00	2024-Q4
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	NEW	—	10,000	—	$13.7K	2024-Q3

6 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).

Insider Transactions

Date	Insider	Title	Type	Shares	Price	Value
Jan 30, 2026	Cobourn Steven P.	Chief Financial Officer	A	14,670	$0.00	$0.00
Jan 30, 2026	Richman Michael	President & CEO	A	38,190	$0.00	$0.00
Jan 30, 2026	Mayer Timothy	Chief Operating Officer	A	14,670	$0.00	$0.00
Jan 30, 2026	Guha Udayan	Chief Medical Officer	A	14,670	$0.00	$0.00
Jan 30, 2026	Kundu Sourav	Sr VP, Dev. & Mfg.	A	8,270	$0.00	$0.00
Jan 30, 2026	Shaw Kevin G.	Sr VP, General Counsel	A	8,270	$0.00	$0.00

3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 3.7/10.

NEUTRAL 8-K 3/10

NextCure reported Q1 2026 net loss of $9.8M ($1.87 per share), in line with consensus of $1.85. Cash

May 7, 2026

NEUTRAL DEFA14A 3/10

NextCure, Inc. filed a definitive proxy statement for its 2026 Annual Meeting, where shareholders wi

Apr 24, 2026

NEUTRAL 8-K 5/10

NextCure reported its full year 2025 financial results, showing a net loss of $55.8 million, a sligh

Mar 5, 2026

NEUTRAL 4/10

NextCure announced initiation of dose optimization for its CDH6-directed ADC SIM0505 in platinum-res

May 4, 2026

NEUTRAL 4/10

NextCure announced that Phase 1 data for SIM0505, an investigational antibody-drug conjugate targeti

Apr 21, 2026

NEUTRAL 5/10

NextCure provided a business update and reported full-year 2025 financial results, highlighting anti

Mar 5, 2026

Current analyst consensus: Strong Buy (89% buy). Based on 9 analysts: 3 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$19.33 mean target +91.2% upside Strong Buy (1.33)

$15.00 Low $25.00 High

Metric	Value
Current Price	$10.11
Target Low	$15.00
Target Mean	$19.33
Target Median	$18.00
Target High	$25.00
# Analysts	3
Recommendation	Strong Buy (1.33)

Earnings Estimates & Revisions

Period	EPS Avg	EPS Low	EPS High	EPS Growth	30d Rev.	Up/Down	Rev. Avg	Rev. Growth	Analysts
Current Q 2026-06-30	$-1.86	$-1.89	$-1.84	83.5%	+6.8%	2↑ 0↓	$0.0B	0.0%	2
Next Q 2026-09-30	$-1.63	$-1.96	$-1.30	49.4%	+21.3%	2↑ 0↓	$0.0B	0.0%	2
Current FY 2026-12-31	$-6.93	$-7.69	$-6.17	64.7%	+15.6%	2↑ 1↓	$0.0B	0.0%	2
Next FY 2027-12-31	$-8.35	$-10.41	$-5.49	-20.5%	-32.3%	0↑ 1↓	$0.0B	0.0%	3

Current Quarter EPS Revision History

Timepoint	EPS Estimate	Change
Current	$-1.865
7d ago	$-1.840	-0.025
30d ago	$-2.000	+0.135
60d ago	$-2.000	+0.135
90d ago	$-1.990	+0.125

1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.

Individual Analyst Actions

Date	Analyst Firm	Action	Previous Rating	New Rating
May 11, 2026	LUCID CAPITAL MARKETS	INITIATE	—	Buy

Monthly Consensus History

Period	Strong Buy	Buy	Hold	Buy %
May 1, 2026	3	5	1	89%
Apr 1, 2026	3	5	1	89%
Mar 1, 2026	3	5	1	89%
Feb 1, 2026	3	5	1	89%
Jan 1, 2026	3	5	1	89%

Strong BuyBuyHoldSellStrong Sell

∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

May 7, 2026

earnings

NextCure Provides Business Update and Reports First Quarter 2026 Financial Results

BELTSVILLE, Md., May 07, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Eqod-6U2x2h9yL5PHSkUGmxXOejC9FfnghBi7fAOjJ

May 4, 2026

fda

NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers

BELTSVILLE, Md., May 04, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=KoHgS0Tvm5Mfje1Jpk49YUqgPN0kPbhZuR5-sGEaNPQ

Apr 29, 2026

earnings_calendar

NXTC Q1 2026 Earnings Scheduled — 2026-04-29

Apr 21, 2026

fda

NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026

Poster to be presented at the American Society for Clinical Oncology on Monday, June 1, 2026 <pre>Poster to be presented at the American Society for C

Apr 7, 2026

other

NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer

BELTSVILLE, Md., April 07, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=JTrhxTq3XyZDgJuypnsGs3ZXqT-Unsp4-Msr_9brl

Mar 5, 2026

announcement

NextCure Provides Business Update and Reports Full Year 2025 Financial Results

BELTSVILLE, Md., March 05, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=t7Is3x6u0WekRf_isez_1BVqzul_u2JMQDXHI0CIe

Mar 4, 2026

earnings_calendar

NXTC Q4 2025 Earnings After Market Close — 2026-03-04